Biogen Inc.'s stock was slightly lower Tuesday, shedding early gains made after the company and Belgian partner UCB announced positive results in a late-stage trial of a treatment for the chronic ...

Biogen and UCB said Tuesday that an experimental drug reduced disease activity and symptoms of systemic lupus, achieving the primary goal of a placebo-controlled Phase 3 study.

UCB and Biogen are advancing dapirolizumab pegol with the objective to address the substantial unmet... Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in ...

UCB Adriaan Snauwaert +32 497 70 23 46 [email protected] Biogen Jack Cox +1 781 464 3260 [email protected]: INVESTOR CONTACTS: UCB Antje Witte +32 2 559 9414 [email protected] ...

Biogen, UCB mark late-stage trial win for autoimmune disease therapy. Sep. 24, 2024 6:41 AM ET Biogen Inc. (BIIB) Stock, UCBJY Stock, UCBJF Stock By: Dulan Lokuwithana, SA News Editor 2 Comments.

UCB and Biogen are initiating a second Phase 3 trial of dapirolizumab pegol in 2024, PHOENYCS FLY. Participants from the PHOENYCS GO study will continue to be followed in a long-term open-label study.

Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus ...

[email protected] Biogen Jack Cox + 1 781 464 3260 [email protected]: INVESTOR CONTACTS: UCB Antje Witte, +32 2 559 9414 [email protected] Biogen Chuck Triano +1 781 464 2442 IR ...

Biogen Inc.’s stock was slightly lower Tuesday, shedding early gains made after the company and Belgian partner UCB announced positive results in a late-stage trial of a treatment for the ...

Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary ...